GLPwatch
Saxenda for Obesity
liraglutide · FDA-approved
Last updated 2026-05-28 15:46 UTCSaxenda (liraglutide) is FDA-approved for the treatment of obesity.
AI summary of the sources below.
| Drug | Saxenda (liraglutide) |
|---|---|
| Condition | Obesity |
| Approval status | FDA-approved |
| Research papers | 50 |
Saxenda is FDA-approved for obesity. See the current label on the Saxenda page.
Research on liraglutide for obesity (50)
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.
- Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
- Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
- Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
- Liraglutide causes large and rapid epicardial fat reduction.
- Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
- GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.